News round-up for 18-22 September by DDW Digital Content Editor Diana Spencer.
As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have also reported on vaccine trials for a number of other conditions, including Nipah virus, rabies and lung cancer.
The top stories:
The EU has historically been a leader in vaccine research, development and manufacturing, but is now seeing a decline in vaccine research, according to data published by Vaccines Europe (VE).
The University of Oxford has revealed that researchers are currently in the advanced stages of preparing for a clinical trial of a Nipah vaccine using the ChAdOx1 vector.
Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies.
IO Biotech has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as first-line therapy.
ICON and the US Biomedical Advanced Research and Development Authority (BARDA) will execute a clinical trial to evaluate the effectiveness of next-generation Covid-19 vaccine candidates.